Premium Nahrungsergänzungsmittel | artgerecht

Hexarelin: Effects, Uses and Research

Hexarelin is a synthetic growth hormone secretagogue that stimulates the release of growth hormone and is used in biomedical research.

Regular tips about health Regular tips about health

Things worth knowing about "Hexarelin"

Hexarelin is a synthetic growth hormone secretagogue that stimulates the release of growth hormone and is used in biomedical research.

What is Hexarelin?

Hexarelin (also known as Examorelin) is a synthetic hexapeptide belonging to the class of growth hormone secretagogues (GHS). Developed in the 1990s, it selectively binds to the ghrelin receptor (GHSR-1a), thereby stimulating the release of growth hormone (GH) from the pituitary gland. Hexarelin is considered one of the most potent peptides of its class and has been extensively studied in biomedical research.

Mechanism of Action

Hexarelin exerts its effects primarily through two mechanisms:

Binding to the GHSR-1a receptor: By activating the ghrelin receptor in the pituitary gland and hypothalamus, Hexarelin directly stimulates the release of growth hormone into the bloodstream.
Inhibition of somatostatin: Hexarelin partially suppresses the action of somatostatin, a hormone that inhibits GH secretion, thereby amplifying the GH response.

In addition, specific binding sites for Hexarelin have been identified in cardiac tissue, independent of the growth hormone pathway. These so-called CD36 receptors mediate cardioprotective effects, making Hexarelin a subject of research in cardiology.

Medical Applications and Research Context

Hexarelin remains primarily in the preclinical and clinical research stage. Potential areas of application include:

Growth hormone deficiency: Hexarelin has been investigated in clinical studies for the diagnosis and treatment of GH deficiency in both children and adults.
Heart failure and cardioprotection: Preclinical studies suggest that Hexarelin possesses cardioprotective properties and may improve cardiac function in heart failure.
Cachexia and muscle wasting: Due to its anabolic properties, Hexarelin is being explored as a potential therapeutic approach in conditions involving muscle wasting, such as cancer cachexia or age-related sarcopenia.
Age-related GH decline: Growth hormone production decreases with age, and Hexarelin is being studied as a potential means of counteracting this decline.

Dosage and Administration

In clinical studies, Hexarelin has been administered primarily intravenously, subcutaneously, or intranasally. Typical study dosages ranged from 1 to 2 µg/kg of body weight. It is important to emphasize that Hexarelin is not an approved pharmaceutical for clinical use in humans and must be used exclusively for research purposes. Self-administration without medical supervision is strongly discouraged.

Side Effects and Safety Profile

The following side effects have been observed in clinical studies:

Elevated cortisol and prolactin levels following administration
Water retention (edema)
Fatigue and drowsiness
Tingling or numbness in the extremities
With prolonged use: possible desensitization of growth hormone receptors (tachyphylaxis)

Long-term safety data in humans are limited, as Hexarelin has not received market authorization to date.

Comparison with Other Growth Hormone Secretagogues

Compared to other GHS such as GHRP-2, GHRP-6, or Ipamorelin, Hexarelin is considered particularly potent in stimulating GH release. Unlike GHRP-6, Hexarelin has a less pronounced appetite-stimulating effect. Ipamorelin displays a more selective action profile with fewer side effects on cortisol and prolactin levels, while Hexarelin stands out for its cardioprotective effects, which are less evident with other GHS peptides.

Legal Status

Hexarelin is not approved as a pharmaceutical in most countries and is listed on the World Anti-Doping Agency (WADA) Prohibited List. Its use in competitive sports is therefore banned. In some countries, it is available as a research chemical but may not be marketed for human use.

References

Ghigo E. et al. - Growth hormone-releasing peptides: clinical and basic aspects. In: Endocrine Reviews, 18(6), 1997, pp. 835–838.
Muccioli G. et al. - Hexarelin, a growth hormone-releasing peptide, binds to a specific receptor in rat heart. In: Endocrinology, 139(12), 1998, pp. 4924–4930.
World Anti-Doping Agency (WADA) - Prohibited List 2024. Available at: https://www.wada-ama.org

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.